The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14. (2019)

First Author: Drexler B
Attributed to:  Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.17863/cam.34195

Publication URI: https://www.repository.cam.ac.uk/handle/1810/286886

Type: Journal Article/Review